Vertex Eyes Expansion Beyond Cystic Fibrosis with Planned $10B Crinetics Buyout
Palsonify®Positive
AI Analysis
Summary
Vertex Pharmaceuticals plans to acquire Crinetics Pharmaceuticals for $10 billion to expand beyond cystic fibrosis into endocrine diseases. Crinetics' lead marketed product Palsonify® (paltusotine) was FDA-approved in September 2025 as the first once-daily oral therapy for acromegaly.
Importance:8/10
Sentiment:
0.70
M&Aacquisitionendocrine diseasesacromegalyexpansion
Read the original article
Published by GEN - Genetic Engineering & Biotech News on July 7, 2026 8:41 PM